All In Biotech

Drug Trial Radar · NCT02845466

Study of Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound Healing

Proof of Concept Study of Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound Healing

Last checked: Nov 20, 2026Latest source record: Apr 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

80

Planned (sponsor's estimate)

Start

Aug 2018

Primary completion

Sep 2020

Study completion Sep 2020

Sponsor

Lead sponsor
McMaster UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Canadian Institutes of Health Research (CIHR)
First posted
Jul 27, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Leg and foot ulcers due to venous disease or diabetes are chronic wounds that can take 6 or more months to heal. Growth factors have been used to try and improve this healing, however, many such studies have failed, and that is thought to be due enzymes in the wound that degrade the growth factors and prevent them from working. This is a proof of concept study that will evaluate the treatment of chronic leg ulcers with topically applied growth factors that are combined with a therapy to prevent their inactivation in the wound.

Conditions

  • Venous Ulcer
  • Foot Ulcer, Diabetic

Interventions

  • BecaplerminBiological

    0.25 cm of 100 µg/g Becaplermin gel topically per 1cm² of ulcer area applied 3 times per week for 6 weeks.

  • Promagran DressingDevice

    44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC wound dressing applied 3 times per week for 4 weeks.

  • Placebo DressingDevice

    Inactive wound dressing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Level of Applied Growth Factors in Chronic Wound FluidTime frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hamilton General Hospital

    Hamilton, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.